Courtesy www.franchiseindia.com
New Delhi: Drug Controller General of India (DCGI) on Friday approved restricted emergency use of Zydus Cadila’s ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infections in adults.
The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of COVID-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.
“A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup,” the company said in a filing.
New Delhi: Bangladesh’s interim government on Monday sent a diplomatic note to India asking the…
Bhubaneswar: Indian Renewable Energy Development Agency Limited (IREDA) has sanctioned over Rs 3,000 crore for…
Raipur: In a significant observation, the Chhattisgarh High Court has said that engaging in sexual intercourse…
Cuttack: The Orissa High Court on Monday reportedly directed the state government to immediately fill…
Bhubaneswar: Over 40 youths, lured to Maldives with promises of lucrative jobs in a private…
London: After a number of Sikhs living in the UK alleged that they were being…
This website uses cookies.